A securities class action has been filed in the USDC – N.J. against Organon & Co. (OGN) (“Organon” or the “Company”), on behalf of all persons and entities that purchased or otherwise acquired Organon common between October 31, 2024, and April 30, 2025, both dates inclusive (the “Class Period”).
Organon is a global healthcare company with a primary focus on improving the health of women throughout their lives. The Company develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health, biosimilars and established brands. Organon operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
The Complaint alleges that the Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon’s priorities, particularly, related to capital allocation through quarterly dividends. Notably, Defendants concealed the high priority of Organon’s debt reduction strategy following the Company’s acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend.
Following this news, the price of Organon’s common stock declined dramatically. From a closing market price of $12.93 per share on April 30, 2025, Organon’s stock price fell to $9.45 per share on May 1, 2025, a decline of more than 27% in the span of just a single day.
If you purchased Organon common stock during the Class Period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.